These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 31929762)

  • 1. Attenuation of Wnt/β-catenin signaling in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Chen CB; Chang WC; Wu MY; Kao TY; Wang YW; Wang CW; Chen CJ; Chung WH; Su SC
    Int J Biol Sci; 2020; 16(2):353-364. PubMed ID: 31929762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stevens-Johnson syndrome and toxic epidermal necrolysis: risk factors, causality assessment and potential prevention strategies.
    Lin CC; Chen CB; Wang CW; Hung SI; Chung WH
    Expert Rev Clin Immunol; 2020 Apr; 16(4):373-387. PubMed ID: 32154748
    [No Abstract]   [Full Text] [Related]  

  • 3. Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis.
    Chung WH; Hung SI
    J Dermatol Sci; 2012 Jun; 66(3):190-6. PubMed ID: 22541332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients--Treatment and outcome.
    Yamane Y; Matsukura S; Watanabe Y; Yamaguchi Y; Nakamura K; Kambara T; Ikezawa Z; Aihara M
    Allergol Int; 2016 Jan; 65(1):74-81. PubMed ID: 26666483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stevens-Johnson syndrome/toxic epidermal necrolysis mouse model generated by using PBMCs and the skin of patients.
    Saito N; Yoshioka N; Abe R; Qiao H; Fujita Y; Hoshina D; Suto A; Kase S; Kitaichi N; Ozaki M; Shimizu H
    J Allergy Clin Immunol; 2013 Feb; 131(2):434-41.e1-9. PubMed ID: 23111236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinguishing between erythema multiforme major and Stevens-Johnson syndrome/toxic epidermal necrolysis immunopathologically.
    Iwai S; Sueki H; Watanabe H; Sasaki Y; Suzuki T; Iijima M
    J Dermatol; 2012 Sep; 39(9):781-6. PubMed ID: 22458564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CD40/CD40 ligand system is expressed in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum.
    Caproni M; Torchia D; Schincaglia E; Volpi W; Frezzolini A; Schena D; Marzano A; Quaglino P; De Simone C; Parodi A; Barletta E; Fabbri P
    Br J Dermatol; 2006 Feb; 154(2):319-24. PubMed ID: 16433803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry.
    Diphoorn J; Cazzaniga S; Gamba C; Schroeder J; Citterio A; Rivolta AL; Vighi GD; Naldi L;
    Pharmacoepidemiol Drug Saf; 2016 Feb; 25(2):196-203. PubMed ID: 26687641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive assessment of T cell receptor β repertoire in Stevens-Johnson syndrome/toxic epidermal necrolysis patients using high-throughput sequencing.
    Xiong H; Wang L; Jiang M; Chen S; Yang F; Zhu H; Zhu Q; Tang C; Qin S; Xing Q; Luo X
    Mol Immunol; 2019 Feb; 106():170-177. PubMed ID: 30623817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Khalili B; Bahna SL
    Ann Allergy Asthma Immunol; 2006 Sep; 97(3):272-80; quiz 281-3, 320. PubMed ID: 17042130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions.
    Wang CW; Yang LY; Chen CB; Ho HC; Hung SI; Yang CH; Chang CJ; Su SC; Hui RC; Chin SW; Huang LF; Lin YY; Chang WY; Fan WL; Yang CY; Ho JC; Chang YC; Lu CW; Chung WH;
    J Clin Invest; 2018 Mar; 128(3):985-996. PubMed ID: 29400697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Hasegawa A; Abe R
    F1000Res; 2020; 9():. PubMed ID: 32595945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stevens-Johnson Syndrome and toxic epidermal necrolysis: a multi-aspect comparative 7-year study from the People's Republic of China.
    Sun J; Liu J; Gong QL; Ding GZ; Ma LW; Zhang LC; Lu Y
    Drug Des Devel Ther; 2014; 8():2539-47. PubMed ID: 25548516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic markers and danger signals in stevens-johnson syndrome and toxic epidermal necrolysis.
    Chung WH; Hung SI
    Allergol Int; 2010 Dec; 59(4):325-32. PubMed ID: 20962567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new nucleic acid-based agent inhibits cytotoxic T lymphocyte-mediated immune disorders.
    Wang CW; Chung WH; Cheng YF; Ying NW; Peck K; Chen YT; Hung SI
    J Allergy Clin Immunol; 2013 Sep; 132(3):713-722.e11. PubMed ID: 23791505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological response in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Abe R
    J Dermatol; 2015 Jan; 42(1):42-8. PubMed ID: 25355273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in vietnamese spontaneous adverse drug reaction database: A subgroup approach to disproportionality analysis.
    Nguyen KD; Tran TN; Nguyen MT; Nguyen HA; Nguyen HA; Vu DH; Nguyen VD; Bagheri H
    J Clin Pharm Ther; 2019 Feb; 44(1):69-77. PubMed ID: 30129156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of additional i.v. immunoglobulin to steroid therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Aihara M; Kano Y; Fujita H; Kambara T; Matsukura S; Katayama I; Azukizawa H; Miyachi Y; Endo Y; Asada H; Miyagawa F; Morita E; Kaneko S; Abe R; Ochiai T; Sueki H; Watanabe H; Nagao K; Aoyama Y; Sayama K; Hashimoto K; Shiohara T;
    J Dermatol; 2015 Aug; 42(8):768-77. PubMed ID: 25982480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Factors associated with the severity of acute ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis in sub-Saharan Africa].
    Saka B; Dzidzinyo K; Akakpo S; Téclessou J; Nouhou Diori A; Maneh N; Mahamadou G; Gnassingbé W; Abilogun-Chokki A; Mouhari-Toure A; Boubacar YA; Kombaté K; Balo K; Tchangai-Walla K; Pitché P
    Ann Dermatol Venereol; 2018 Apr; 145(4):245-249. PubMed ID: 29487020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Infectious Diseases on the Pathogenesis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
    Okamoto-Uchida Y; Nakamura R; Sai K; Imatoh T; Matsunaga K; Aihara M; Saito Y
    Biol Pharm Bull; 2017; 40(9):1576-1580. PubMed ID: 28867742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.